KPMG in the UK embarked on a journey of transformation during 2013, in pursuit of our strategic goal to dominate professional services. Our Annual Review highlights how we bring real benefits to our clients, our people and society as a whole.
After seven years of turmoil, the banking sector can finally shift focus from cleaning up the debris caused by the financial crisis and start making steps towards delivering sustainable growth and profitability.
Explore why technology firms should choose to invest in the UK. We consider what the UK currently has in its favour as it battles for technology investment.
Technology has revolutionised the day-to-day lives of individuals and organisations alike. But if we're to continue to benefit and to profit from it, and if we're to minimise the potential downsides, we're going to have make some choices.
We help our clients understand current issues and future trends in the world of work, and identify how they can enhance organisational performance through their people.
Explore the opportunities available for school and college leavers at KPMG.
Find out about careers for graduates from all degree disciplines in Audit, Tax, Advisory, Technology, Marketing and HR.
Keep up to date with the latest news and views from KPMG in the UK by following our twitter feed.
KPMG’s leadership blogs brings you insight, opinion and debate from our senior partners and industry experts.
Healthcare systems around the world are in crisis. Patients increasing longevity, rising expectations, unhealthy lifestyles, multiple co-morbidities and healthcare cost inflation are all contributing.
As a result healthcare systems are being forced to find ways to solve a simple but difficult question – how to secure better patient outcomes at a lower cost?The new healthcare landscape is changing dramatically across every market in the world. This is the catalyst which provides pharmaceutical companies with the opportunity to demonstrate its real value! With new ecosystems built around patients, not providers.
In mature markets, medicines constitute roughly 10 of the total healthcare bill. To achieve better patient outcomes for less money, the initial focus has to be the other 90% of the budget.
I believe a much greater partnership between pharmaceutical companies and the wider healthcare eco-system can contribute significantly to the solution.
The new healthcare landscape is changing dramatically across every market in the world. This is the catalyst which provides pharmaceutical companies with the opportunity to demonstrate its real value!
This is a time of Healthcare convergence – where all stakeholders in the healthcare ecosystem will need to work together to achieve one aim: better patient outcomes at a lower cost
With new ecosystems built around patients, not providers.
I see a world where combining the global infrastructure of Pharma with the care experience of providers and risk management experience of payers could create new ways to deliver improved value to the patient.
In every country that I visit I see health systems transforming themselves from a 20th century model of care to a 21st century, emerging economies with a strong Life Science base can provide great services to millions if not billions of people through the development of new technology, new modalities of treatments and new partnerships of models between health systems and life science companies. Patients want more control, they want more information, they want more knowledge - clever life science firms, clever pharmaceuticals will realise patients want to be partners.
I believe there are three strategies for success if Pharmaceuticals are to become a true partner to the wider Healthcare eco-system.
Pharma needs to understand their customer, their challenges and provide solutions to those challenges.
Pharma needs to better anticipate the shifting power structures in the wider healthcare system- it needs to be engaged and partner appropriately in each country in which it operates.
Pharma needs to continue to re-shape its R&D to deliver products and services which will meet future needs and provide an adequate return to shareholders
I believe this approach will ultimately catapult Pharma’s position to the realm of Partner, rather than a supplier.
Pharma has to change.
Global Lead for Life SciencesKPMG in the UK
+44 207 3118512
KPMG LLP, a UK limited liability partnership, and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. All rights reserved.
KPMG International Cooperative ("KPMG International") is a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.